Update on the therapy of Behcet disease

被引:89
作者
Saleh, Zeinab [1 ]
Arayssi, Thurayya [2 ]
机构
[1] Tufts Med Ctr, Boston, MA USA
[2] Weill Cornell Med Coll Qatar, Educ City,POB 24144, Doha, Qatar
关键词
Behcet disease; Behcet syndrome; biologic therapy; therapy; treatment; tumor necrosis factor alpha;
D O I
10.1177/2040622314523062
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Behcet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behcet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behcet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.
引用
收藏
页码:112 / 134
页数:23
相关论文
共 197 条
[1]   Successful use of infliximab in a patient with neuro-Behcet's disease [J].
Abalos-Medina, Gracia Maria ;
Sanchez-Cano, Daniel ;
Ruiz-Villaverde, Gonzalo ;
Ruiz-Villaverde, Ricardo ;
Quirosa Flores, Susana ;
Raya Alvarez, Enrique .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2009, 12 (03) :264-266
[2]   Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease [J].
Abu El-Asrar A.M. ;
Abboud E.B. ;
Aldibhi H. ;
Al-Arfaj A. .
International Ophthalmology, 2005, 26 (3) :83-92
[3]   Infliximab treatment for ocular and extraocular manifestations of Behcet's disease [J].
Accorinti, Massimo ;
Pirraglia, Maria Pia ;
Paroli, Maria Pia ;
Priori, Roberta ;
Conti, Fabrizio ;
Pivetti-Pezzi, Paola .
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2007, 51 (03) :191-196
[4]  
Adan A, 2010, INT OPHTHALMOL, V30, P577, DOI [DOI 10.1007/S10792-010-9372-1, DOI 10.1007/s10792-010-9372-1]
[5]   Behcet's disease: Successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis [J].
Adler, Sabine ;
Baumgartner, Iris ;
Villiger, Peter M. .
ARTHRITIS CARE & RESEARCH, 2012, 64 (04) :607-611
[6]   Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet's disease [J].
Adler, YD ;
Mansmann, U ;
Zouboulis, CC .
DERMATOLOGY, 2001, 203 (04) :322-324
[7]   Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation [J].
Ahn, Joong Kyong ;
Lee, You Sun ;
Jeon, Chan Hong ;
Koh, Eun-Mi ;
Cha, Hoon-Suk .
CLINICAL RHEUMATOLOGY, 2008, 27 (02) :201-205
[8]   Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Beh‡et's disease [J].
Aikawa, Nadia Emi ;
Goncalves, Carla ;
Almeida Silva, Clovis Artur ;
Goncalves, Celio ;
Bonfa, Eloisa ;
de Carvalho, Jozelio Freire .
RHEUMATOLOGY INTERNATIONAL, 2011, 31 (08) :1097-1099
[9]  
AKTULGA E, 1980, HAEMATOLOGICA, V65, P399
[10]   Safety and efficacy of infliximab therapy in active Behcet's uveitis: an open-label trial [J].
Al-Rayes, H. ;
Al-Swailem, R. ;
Al-Balawi, M. ;
Al-Dohayan, N. ;
Al-Zaidi, S. ;
Tariq, M. .
RHEUMATOLOGY INTERNATIONAL, 2008, 29 (01) :53-57